Study confirms sensory loss associated with taste and smell is strongly linked to early coronavirus infection. Based on the findings, people who report olfactory or taste loss are ten times more likely to have COVID-19 than other infections. Patients reported their sensory loss to be profound rather than mild. Encouragingly, the rate of sensory recovery was high, with patients reporting a return of normal smell and taste function within two to four weeks, which matches the time of disease recovery. Researchers also found people who reported sore throats more often tested negative for COVID-19.
A new mathematical model reveals a more realistic picture of the number of likely COVID-19 cases, both in the US and worldwide, compared to reported data.
Mathematical model incorporated several strategies to help flatten the COVID-19 curve, focusing on scarcity in hospital resources over two years. The models showed current physical distancing can help maintain healthcare capacity and reduce infections. The model also allowed for periodic economic and psychological breaks from social restrictions.
An FDA-approved anti-parasitic drug called Ivermectin appears to inhibit and eliminate SARS-CoV-2 in lab-grown cell cultures within 48 hours. Ivermectin shows promise as potential COVID-19 therapy. However, researchers stress the need for further testing and clinical trials in humans to confirm the effectiveness of the drug and appropriate dosage levels.
Biological sequencing of the fusion peptides of SARS-CoV and SARS-CoV-2 found them to be a 93% match. Calcium ions interacting with the fusion peptide alters the peptide's structure, and how it interacts with membranes to promote infection. The findings provide a potential target for antiviral development to treat coronavirus.
Domestic spread of coronavirus transmission via interstate travel is now more of a threat to people in American than from international travel. Findings repeat the need for more widespread diagnostic testing for COVID-19 at the state level and more intense tracking of people exposed to SARS-CoV-2.
EIDD-2801, a new antiviral drug, has the potential to treat coronavirus. A new study reveals the drug can prevent severe lung injury in mouse models and cultured human lung cells infected with COVID-19. The drug will soon be ready for human testing.
Study reveals the official number of confirmed cases of coronavirus is dramatically understated. Data shows, due to insufficient and delayed testing, countries throughout the world have only discovered about 6% of COVID-19 cases. The true number of infections worldwide may already have reached several tens of millions.
Researchers warn that if the US is to avoid the impact on hospitals Italy faces as a result of the coronavirus outbreak, people who are even mildly symptomatic must self isolate to minimize disease transmission.
Researchers explore why COVID-19 is more deadly compared to the flu and other viruses.
A patient who tested positive for COVID-19 developed acute necrotizing encephalitis (ANE) as a result of the coronavirus infection. An MRI scan revealed the patient had lesions in the thalamus and temporal lobes, areas of the brain implicated in consciousness, sensation, and memory function. Researchers advise doctors to look out for COVID-19 patients who present with altered levels of consciousness, as this may be symptomatic of ANE.